New Share Issue | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

September 2018

New Share Issue

The board of directors of IDL Biotech AB (publ) has resolved to make a new share issue of approximately SEK 39,4 million before issue costs.

Read the press release here 

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

IDL Biotech

Skip this intro